Landesfrauenklinik, Senologie und Brustzentrum
Welcome,         Profile    Billing    Logout  
 7 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bjelic-Radisic, Vesna
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
GBG Forschungs GmbH, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
TREAT ctDNA, NCT05512364: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

Recruiting
3
220
Europe
Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG
European Organisation for Research and Treatment of Cancer - EORTC, Breast International Group, Menarini Group
ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
07/28
05/30
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
ADAPTHER2-IV, NCT05704829: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

Recruiting
2
402
Europe
Trastuzumab deruxtecan, ENHERTU, Standard-of-Care, Chemotherapy+T+P
West German Study Group, AstraZeneca
HER2-positive Early Breast Cancer
06/26
06/28
ADAPT-TN-III, NCT06081244: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC

Recruiting
2
348
Europe
Sacituzumab govitecan, Trodelvy, Pembrolizumab, Keytruda
West German Study Group, Gilead Sciences, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
09/29
09/29
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT03515993: Follow-up in Gynecological Cancer Survivors

Active, not recruiting
N/A
1100
Europe, RoW
European Organisation for Research and Treatment of Cancer - EORTC
Gynecologic Cancer
03/24
04/24
VISION I, NCT04289935: Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer

Recruiting
N/A
420
Europe, RoW
Vacuum assisted biopsy (VAB)
Klinik Hirslanden, Zurich, Oncoplastic Breast Consortium (OPBC)
Breast Cancer
06/25
06/25
TAXIS, NCT03513614: Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer

Recruiting
N/A
1500
Europe, Canada, US, RoW
Tailored axillary surgery - both Arms, Radiotherapy - Arm A, Radiotherapy - Arm B
University Hospital, Basel, Switzerland, ETOP IBCSG Partners Foundation, Austrian Breast Cancer Study Group
Node-positive Breast Cancer
12/29
12/36
OPBC-02PREPEC, NCT04293146: Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy

Active, not recruiting
N/A
382
Europe, US
pre-pectoral IBBR, sub-pectoral IBBR
University Hospital, Basel, Switzerland, Swiss National Science Foundation
Breast Reconstruction, Implant-Based Breast Reconstruction (IBBR)
05/25
02/33
PROOFS, NCT05792150: -Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS

Recruiting
N/A
1470
Europe
West German Study Group, Agendia
Female Breast Cancer
03/35
06/35
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bjelic-Radisic, Vesna
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
GBG Forschungs GmbH, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
TREAT ctDNA, NCT05512364: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

Recruiting
3
220
Europe
Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG
European Organisation for Research and Treatment of Cancer - EORTC, Breast International Group, Menarini Group
ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
07/28
05/30
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
ADAPTHER2-IV, NCT05704829: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

Recruiting
2
402
Europe
Trastuzumab deruxtecan, ENHERTU, Standard-of-Care, Chemotherapy+T+P
West German Study Group, AstraZeneca
HER2-positive Early Breast Cancer
06/26
06/28
ADAPT-TN-III, NCT06081244: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC

Recruiting
2
348
Europe
Sacituzumab govitecan, Trodelvy, Pembrolizumab, Keytruda
West German Study Group, Gilead Sciences, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
09/29
09/29
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT03515993: Follow-up in Gynecological Cancer Survivors

Active, not recruiting
N/A
1100
Europe, RoW
European Organisation for Research and Treatment of Cancer - EORTC
Gynecologic Cancer
03/24
04/24
VISION I, NCT04289935: Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer

Recruiting
N/A
420
Europe, RoW
Vacuum assisted biopsy (VAB)
Klinik Hirslanden, Zurich, Oncoplastic Breast Consortium (OPBC)
Breast Cancer
06/25
06/25
TAXIS, NCT03513614: Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer

Recruiting
N/A
1500
Europe, Canada, US, RoW
Tailored axillary surgery - both Arms, Radiotherapy - Arm A, Radiotherapy - Arm B
University Hospital, Basel, Switzerland, ETOP IBCSG Partners Foundation, Austrian Breast Cancer Study Group
Node-positive Breast Cancer
12/29
12/36
OPBC-02PREPEC, NCT04293146: Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy

Active, not recruiting
N/A
382
Europe, US
pre-pectoral IBBR, sub-pectoral IBBR
University Hospital, Basel, Switzerland, Swiss National Science Foundation
Breast Reconstruction, Implant-Based Breast Reconstruction (IBBR)
05/25
02/33
PROOFS, NCT05792150: -Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS

Recruiting
N/A
1470
Europe
West German Study Group, Agendia
Female Breast Cancer
03/35
06/35

Download Options